直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Federal Circuit IP Blog

When to Consider Expert Testimony for Special Purpose Computer-Implemented Means-Plus-Function Claims

October 20, 2023

Authored and Edited by Emma N. Ng; Ryan V. McDonnell; Esther H. Lim

In Sisvel International S.A. v. Sierra Wireless, Inc., Nos. 2022-1493, 2022-1547 (Fed. Cir. Oct. 6, 2023), the Federal Circuit affirmed-in-part, vacated-in-part, and remanded to the Patent Trial and Appeal Board (“Board”).

Cross-Appellants filed a petition for an IPR of claims 1-10 of U.S. Patent No. 6,529,561 (“the ’561 patent”). The ’561 patent relates to methods of channel coding when transmitting data in radio systems. After instituting the IPR, the Board found claims 1-3 and 9 unpatentable for obviousness and claims 4-8 and 10 not unpatentable. The claims were examined under pre-AIA law.

The Federal Circuit held that the Board erred in analyzing the “means for detection” limitation of claims 5 and 10. The Court noted that its precedents recognize two distinct groups for special purpose computer-implemented means-plus-functions claims: (1) where a defining structure is totally absent from the specification and expert testimony cannot be considered; or (2) where a defining structure is “arguably” adequately disclosed in the specification and expert testimony may be considered. While the Board determined that the “means for detection” limitation fell into the first group and did not consider expert testimony, the Federal Circuit disagreed because the specification identified the name of relevant software protocols. Thus, the limitation properly fell into the second group even though the steps corresponding to the protocols were not expressly described in the specification. The Federal Circuit thus remanded for the Board to consider expert testimony and address whether the protocols identified disclosed a sufficient structure to satisfy 35 U.S.C. § 112.

Tags

Written description (35 USC § 112), means-plus-function claim

Related Practices

Appeals, Issues, and Legal Strategy

Federal Circuit and Supreme Court Appeals

Global IP Enforcement, Litigation, and Trials

Related Industries

Communications

Related Offices

Washington, DC

Contacts

Emma N. Ng
Associate
Washington, DC
+1 202 408 4149
Email
Ryan V. McDonnell
Associate
Washington, DC
+1 202 408 4167
Email
Esther H. Lim
Partner and Chief Community Officer
Washington, DC
+1 202 408 4121
Email

Copyright © 2023 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Charitable

Bridges From School to Work Gala 2026

June 22, 2026

Washington, DC

Charitable

Banding Together 2026

June 18, 2026

Washington, DC

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Webinar

Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement

May 18, 2026

Webinar

Articles

COPPA’s Amended Rule Is Now in Full Effect: What Operators Need to Know

May 15, 2026

Federal Circuit IP Blog

When “and” and “e.g.” Matter: Federal Circuit Revives VLSI vs. Intel Case

May 14, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP